Dual Monoclonal Antibody Therapy for a Severe Asthma Patient

• Main Authors: Christian Domingo (Author), Xavier Pomares (Author), Anisi Morón (Author), Ana Sogo (Author)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2020-09-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

IntroductionOmalizumab, the first biological treatment for severe allergic bronchial asthma, has been on the market for more than a decade. Omalizumab was initially considered to be an IgE-blocking agent, and therefore, an inhibitor of the Th2 (allergic or adaptive) cascade. More recently, other mon...